Show simple item record

dc.contributor.authorNavalkissoor, S
dc.contributor.authorFlux, G
dc.contributor.authorBomanji, J
dc.date.accessioned2018-02-19T16:43:03Z
dc.date.issued2017-10
dc.identifier.citationClinical medicine (London, England), 2017, 17 (5), pp. 462 - 468
dc.identifier.issn1470-2118
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1352
dc.identifier.eissn1473-4893
dc.identifier.doi10.7861/clinmedicine.17-5-462
dc.description.abstractThis article discusses the important role of nuclear medicine imaging and therapy in the management of neuroendocrine tumours (NETs). Somatostatin receptor scintigraphy has a high impact on patient management versus conventional imaging. Molecular radiotherapy is an important part of the management of patients with NETs. Selection of patients for molecular radiotherapy in NETs is based on uptake on their radionuclide imaging study. The imaging agent has the same mechanism of uptake as the therapeutic agent. Thus, the imaging study preselects patients that are likely to concentrate radiation within their tumours.
dc.formatPrint
dc.format.extent462 - 468
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectNeuroendocrine Tumors
dc.subjectRadionuclide Imaging
dc.titleMolecular radiotheranostics for neuroendocrine tumours.
dc.typeJournal Article
rioxxterms.versionofrecord10.7861/clinmedicine.17-5-462
rioxxterms.licenseref.startdate2017-10
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfClinical medicine (London, England)
pubs.issue5
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics/Radioisotope Physics (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics/Radioisotope Physics (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume17en_US
pubs.embargo.termsNot known
icr.researchteamRadioisotope Physicsen_US
dc.contributor.icrauthorFlux, Glennen
dc.contributor.icrauthorMarsden,en


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record